Recombinant human IL-11 (oprelvekin) was FDA-approved in 1998 (184, 275, 276) for the treatment of thrombocytopenia (low platelet levels) in myelosuppressive chemotherapy, as a substitute for platelet transfusions. This evidence concerns the gene IL11 and Thrombocytopenia.